High Purity Raw Powder Oestradiol 17-Heptanoate CAS 4956-37-0

Product Details:

Place of Origin: China
Brand Name: Changland
Certification: GMP&ISO
Model Number: 4956-37-0

Payment & Shipping Terms:

Price: USD 295 Per 100g,USD 2200 Per 1Kg
Packaging Details: 1KG per foil bag, 25KG per drum.
Delivery Time: 5 working days
Payment Terms: MoneyGram, Western Union, T/T, D/P, D/A, L/C
Supply Ability: 200KG per month
Category:

Description

High Purity Raw Powder Oestradiol 17-Heptanoate CAS 4956-37-0

Description

Cas: 4956-37-0 MF: C25H36O3
MW: 384.56 EINECS No.: 225-599-8
Boiling Point: 509.5±50.0 °C(Predicted) Melting Point: 94-96°
Density: 1.11±0.1 G/cm3(Predicted) Storage: Sealed In Dry,Room Temperature
High Light:

Oestradiol 17-Heptanoate

,

4956-37-0 Oestradiol 17-Heptanoate

 

Hot Sale High Purity Raw Powder Oestradiol 17-Heptanoate CAS 4956-37-0

 

Product introduction

 

Product name Oestradiol 17-heptanoate
CAS No. 4956-37-0
MF C25H36O3
MW 384.56
EINECS No. 225-599-8
Density 1.11±0.1 g/cm3(Predicted)
Boiling Point 509.5±50.0 °C(Predicted)
Melting Point 94-96°

 

Descripition:

 

Estradiol enantate (E2-EN or EEn), also spelled estradiol enanthate and sold under the brand names Perlutal and Topasel among others, is an estrogen medication which is used in hormonal birth control for women. It is formulated in combination with dihydroxyprogesterone acetophenide (DHPA; algestone acetophenide), a progestin, and is used specifically as a combined injectable contraceptive. Estradiol enantate is not available for medical use alone. The medication, in combination with DHPA, is given by injection into muscle once a month.

Side effects of estradiol enantate include breast tenderness, breast enlargement, nausea, headache, and fluid retention. Estradiol enantate is a synthetic estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It is an estrogen ester and a long-lasting prodrug of estradiol in the body. Because of this, it is considered to be a natural and bioidentical form of estrogen.

Estradiol enantate was first described by 1954, and was first studied in combination with DHPA as a combined injectable contraceptive in 1964.The combination was introduced for clinical use by the mid-1970s. Estradiol enantate is not available as a standalone medication (i.e., by itself without DHPA). The combination is available in Latin America and Hong Kong, and was also previously marketed in Spain and Portugal.

 

Uses:

 

Hormones and regulation of endocrine function